# Grifols S.A. American (GRFS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $7.80, market value $5.3 billion.

## Valuation
- **P/E (trailing): 10.1×** (5-yr avg 60.7×, 3-yr avg 78.0×). Grifols S.A. American trades at 10.1× trailing earnings, well below its own five-year average of 60.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 5.4×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.03**. A PEG of 0.03 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.6×**. Each dollar of revenue is priced at 0.6×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.7×**. The shares trade at 1.7× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 8.4×**. Enterprise value is 8.4× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 10.7%** (5-yr avg 4.6%). Free cash flow equals 10.7% of the market value, above its five-year average of 4.6%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 9.9%**. The inverse of the P/E: 9.9% of the price is earned each year.

## Profitability
- **Gross margin: 37.0%**. Grifols S.A. American keeps 37.0% of revenue after the direct cost of what it sells.
- **Operating margin: 16.2%**. 16.2% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 5.3%**. 5.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 7.6%**. 7.6% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 7.0%**. Return on all capital, debt included, is 7.0%.
- **Return on assets: 2.2%**. Each dollar of assets produces 2.2% of profit.

## Growth
- **Revenue growth (1 yr): 4.3%** (3-yr 7.5%/yr, 5-yr 7.1%/yr). Revenue grew 4.3% over the last year, against 7.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 156.5%** (3-yr 29.8%/yr, 5-yr -8.1%/yr). Earnings per share rose 156.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 1.81**. Debt is 1.81 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 5.5×**. It would take 5.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 2.51** (quick 0.88). Current assets cover the next year's liabilities 2.51 times.
- **Altman Z-score: 1.41**. A Z-score of 1.41 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 3.61%** ($0.28 per share, trailing). Grifols S.A. American yields 3.61%, an income-level yield.
- **Payout ratio: 32%**. 32% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 1**. 1 straight year of increases.
- **Dividend growth (5 yr): -3.0%/yr**. The dividend has not grown over five years.

## Price and momentum
- **Total return (1 yr): -20.2%** (YTD -15.5%, 3-mo 3.5%). The shares are down 20.2% over twelve months including dividends.
- **From 52-week high: -23.8%** (12.1% above the low). Trading 24% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 0.90** (volatility 32%). Beta of 0.90 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GRFS · Page: https://foliofundamentals.com/stocks/grfs

Not investment advice.